Evaxion A (EVAX) Non-Current Debt (2021 - 2025)
Evaxion A posted quarterly Non-Current Debt of $5.3 million for Q4 2025, down 33.23% year-on-year from $8.0 million in Q4 2024, and down 40.79% on a QoQ basis from $9.0 million in Q2 2025.
Evaxion A (EVAX) has 5 years of Non-Current Debt data on file, last reported at $5.3 million in Q4 2025.
- For the quarter ending Q4 2025, Non-Current Debt fell 33.23% year-over-year to $5.3 million; the trailing twelve-month figure through Dec 2025 stood at $5.3 million (down 33.23% YoY), and the FY2025 full-year result was $5.3 million, down 33.23% from the prior year.
- Non-Current Debt for Q4 2025 stood at $5.3 million, down from $9.0 million in the prior quarter.
- Across five years, Non-Current Debt topped out at $9.0 million in Q2 2025 and bottomed at $1.0 million in Q4 2021.
- The 5-year median for Non-Current Debt is $7.9 million (2022), against an average of $6.6 million.
- The widest annual swing landed in 2022, when Non-Current Debt surged 653.26%; it then plunged 33.23% in 2025.
- A 5-year view of Non-Current Debt shows it stood at $1.0 million in 2021, then soared by 653.26% to $7.9 million in 2022, then climbed by 7.95% to $8.5 million in 2023, then slipped by 5.67% to $8.0 million in 2024, then slumped by 33.23% to $5.3 million in 2025.
- The last three Non-Current Debt figures came in at $5.3 million (Q4 2025), $9.0 million (Q2 2025), and $8.0 million (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 319.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 105.94 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.99 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 5.35 Mn |
| Dec 31, 2025 | 5.35 Mn |
| Jun 30, 2025 | 9.03 Mn |
| Jun 30, 2025 | 9.03 Mn |
| Dec 31, 2024 | 8.01 Mn |
| Dec 31, 2024 | 8.01 Mn |
| Jun 30, 2024 | 8.26 Mn |
| Jun 30, 2024 | 8.26 Mn |
| Dec 31, 2023 | 8.49 Mn |
| Dec 31, 2023 | 8.49 Mn |
| Jun 30, 2023 | 8.08 Mn |
| Jun 30, 2023 | 8.08 Mn |
| Dec 31, 2022 | 7.86 Mn |
| Dec 31, 2022 | 7.86 Mn |
| Jun 30, 2022 | 7.34 Mn |
| Jun 30, 2022 | 7.34 Mn |
| Mar 31, 2022 | 7.72 Mn |
| Mar 31, 2022 | 7.72 Mn |
| Dec 31, 2021 | 1.04 Mn |
| Dec 31, 2021 | 1.04 Mn |
| Sep 30, 2021 | 1.10 Mn |
| Sep 30, 2021 | 1.10 Mn |